NOT ALL ONE-MONTH DAPT TRIALS ARE CREATED EQUAL

ONYX ONE IS MORE RIGOROUSLY DESIGNED THAN XIENCE 28[1] AND POEM[2]

Trial	Size	Comparator	Randomised Control Trial	Included ACS Patients	Angiographic Exclusions	HBR Exclusions	Primary Endpoint Follow-up
Onyx ONE Global Trial	1,996	BioFreedom™* DCS	✓	✓	None	None	12 months
Onyx ONE Clear Analysis	1,506	Performance Goal	✗	✓	None	None	12 months
XIENCE 28	1,392	Single-arm Historical Control (XIENCE V USA Study) 2008–2011	✗	No STEMI	**Excluded:** Left main CTO ISR Overlapping stents SVG	Planned surgery	6 months
POEM (Synergy™* Stent)	443	Objective Performance Criteria	✗	✓	None	None	12 months

ONYX ONE STUDIED A MORE COMPLEX HIGH BLEEDING RISK (HBR) POPULATION THAN XIENCE 28[1] AND POEM[2]

Trial	Lesion Characteristics			Patient Characteristics	
	B2/C	Average Stented Length	Moderate/Severe Calcified Lesions	ACS	Prior MI
Onyx ONE Global Trial†	80%	38 mm	46%	53%	26%
Onyx ONE Clear Analysis	79%	37 mm	50%	49%	26%
XIENCE 28	36%	27 mm	Not Reported	34%	16%
POEM (Synergy™ Stent)	49%	24 mm	Not Reported	41%	Not Reported

†Results include the Resolute Onyx DES treated arm.

Medtronic

Resolute Onyx™ DES



DIFFERENT BY DESIGN TO PROMOTE FAST HEALING

Single-wire design provides a fluid range of motion and the conformability needed for superior strut apposition[3]

BioLinx™ biocompatible polymer provides superior thromboresistance[4]

Fast healing as evidenced by nearly 90% strut coverage at 30 days,[5] **providing the option to shorten DAPT**





Less fluorescence (red) is better



Resolute Onyx is the first DES CE indicated for 1-month DAPT in HBR patients based on results from the Onyx ONE Global Study which proved safety and efficacy[6]

CE 2797

*Third-party brands are trademarks of their respective owners.

[1] Mehran R, et al. The Xience Short DAPT Program: Xience 90/28. Evaluating the Safety of 3-month and 1-month DAPT in HBR Patients. Presented at TCT Congress 2020.
[2] Stefanini G, et al. The POEM Study: One-Month DAPT in HBR Patients. Presented at PCR 2021.
[3] Data on file at Medtronic.
[4] Jinnouchi H, Sato Y, Cheng Q, et al. Thromboresistance and endothelial healing in polymer-coated versus polymer-free drug-eluting stents: Implications for short-term dual anti-platelet therapy. *Int J Cardiol*. March 15, 2021;327:52-57.
[5] Roleder T, Kedhi E, Berta B, et al. Short-term stent coverage of second-generation zotarolimus-eluting durable polymer stents: Onyx one-month optical coherence tomography study. *Postepy Kardiol Interwencyjnej*. 2019;15(2):143-150.
[6] Windecker S, Latib A, Kedhi E, et al. Polymer-based or Polymer-free Stents in Patients at High Bleeding Risk. *N Engl J Med*. March 26, 2020;382(13):1208-1218.

Medtronic

Europe
Medtronic Intl. Trading SARL
Tel: 41.21.802.7000

Asia Pacific
Medtronic Intl. Ltd.
Tel: 65.6436.5000

Latin America
Medtronic
Tel: 786.709.4200

medtronic.com/OnyxONE